TAS::75 0849::TAS R&D-OTHER SCIENCES-B RES

在西方社会，乳腺癌是一种毁灭性的疾病。对基因的表达进行量化是非常有意义的 HER2/neu(一种生长因子受体)、雌激素受体(ER)和孕激素受体(PR) 乳腺癌由于HER2/neu的表达与高恶性度相关，而且因为 HER2Ineu和ER是抗乳腺癌治疗的靶点(分别是赫赛汀和他莫昔芬)。这个 PR的存在或缺失也有助于诊断肿瘤对他莫昔芬的敏感性，因为PR 表达依赖于内质网的活性。这项检测将量化表达的细胞群体 从活检材料或手术切除获得的肿瘤切片中的HER2/neu、ER和PR； 生物标志物将在单独的光学通道中可视化，并在逐个细胞的基础上通过 荧光显微镜。该检测将以HER2/neu、ER和HER2/neu的半抗原偶联一抗为特色。 PR和二次试剂连接到量子点(ODoIS)，这些量子点永远不会漂白。因此，幻灯片 使用该检测试剂和方法制备的试剂和方法将具有档案质量。此外，ODOT试剂 为这项测试开发的方法将普遍适用于对各种生物标志物进行量化 其他类型的肿瘤，如前列腺癌。

Breast cancer is a devastating affliction in Western Society. It is of high interest to quantify the expression of HER2/neu (a growth factor receptor), the estrogen receptor (ER), and the progesterone receptor (PR) in breast cancer tumors since HER2/neu expression is associated with high malignancy and because HER2Ineu, and ER are targets for anti-breast cancer therapies (Herceptin and tamoxifen, respectively). The presence or absence of PR is also helpful in diagnosing the sensitivity of a tumor to tamoxifen, since PR expression is dependent upon ER activity. The assay will quantify the populations of cells expressing HER2/neu, ER, and PR in the tumor sections obtained from biopsy material or surgical resection; each biomarker will be visualized in a separate optical channel and quantified on a cell by cell basis via fluorescence microscopy. The assay will feature hapten-coupled primary antibodies to HER2/neu, ER, and PR, and secondary reagents conjugated to quantum dots (ODoIS), which never photo bleach. Thus, slides prepared using the assay reagents and methods will be of archival quality. Furthermore, the ODot reagents and methods developed for this assay will be generally applicable for quantifying biomarkers in a wide variety of other tumor types, such as prostate cancer.